Biosimilar medicines’ developments are maintaining their momentum and the 2016 Biosimilars Conference programme delves into strategic discussions regarding:
- Market and regulatory developments in the EU and globally, enlightened by the perspective of healthcare professionals’ and patients’ experiences
- Pharmacovigilance and clinical practice - what can be learned from the emerging data?
- The impact of biosimilar medicines on the competitive landscape of biological products, in light of 10 years of market existence
As the 4th conference of its kind, the 2016 programme gives a complete 360-degree overview of biosimilar medicines. Participants will leave the conference with a wealth of new information and an expanded network of contacts.
Generics and Biosimilars Initiative (GaBI) was founded in 2008. GaBI aims to foster the worldwide efficient use of high quality and safe medicines at an affordable price, thus advancing and supporting the idea of accessible, affordable and sustainable health care. GaBI Online (www.gabionline.net) is a one-stop portal for global news on recent developments in the field of generics and biosimilars, a repository of worldwide guidelines and an archive of related scientific information.
GaBI Journal – official Journal of the Generics and Biosimilars Initiative (http://www.gabionline.net) – is an independent, peer reviewed academic Journal. It encompasses all aspects of generic and biosimilar medicines development and use, from fundamental research to clinical application and policies.
- Current regulatory status of biosimilar medicines in the EU and beyond
- Biological medicines in practice - experiences and views of patients, pharmacists, nurses, physicians and hospital managers/ payers (procurers)
- Key learnings from multi-stakeholder dialogue platforms on patients and healthcare professionals’ information needs
- The balance of risk and benefits for biosimilars – where it stands after a decade of biosimilar use
- Interchangeability and switching of biosi
- Clinical experience and real world evidence for biosimilar medicines: what is the state of play in terms of clinical and economic value proposals
What you will learn
- Deal with regulatory requirements, scientific and operational challenges
- Exchange experiences and discuss hot topics with experts
- Update the participant on the current knowledge including regulatory and scientific thinking
- Discuss the necessary conditions for optimal use
Who should attend?
- Regulatory affairs professionals
- Healthcare professionals
- Patient advocates
- Decision makers
Thijs Giezen, PharmD, PhD, MSc •
Medicines Evaluation Board, Netherlands
Julie Marechal-Jamil, MSc • Director, Biosimilar Policy & Science
Medicines For Europe, Belgium
Steffen Thirstrup, MD, PhD • Director, NDA Regulatory Advisory Board
NDA Advisory Services, United Kingdom
Aimad Torqui, MSc • Director, Global Regulatory Policy
Paul Cornes • MD, Oncologist
Bristol Oncology Centre, United Kingdom